Zavesca User Fee Goal In August; EU Review Raises Neurotoxicity Concerns
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
European review documents for Oxford GlycoSciences/Actelion’s Gaucher disease treatment Zavesca raise two concerns that are likely issues in FDA’s review: comparative efficacy to enzyme replacement therapy and neurological adverse events.